Publications by authors named "DongQing Lv"

Antibody-drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker. Here we report the findings from a large-scale, global, multicenter, phase 1 trial evaluating the safety, pharmacokinetics and preliminary efficacy of YL201 in patients with advanced solid tumors refractory to standard therapies.

View Article and Find Full Text PDF

Introduction: Denosumab (Xgeva®) is a standard treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM). This trial was designed to assess the equivalence of LY01011 to denosumab in terms of efficacy and safety.

Materials And Methods: Eligible patients with BM from solid tumors were randomized at a 1:1 ratio to receive 120 mg of LY01011 or 120 mg of denosumab subcutaneously every four weeks during a 12-week double-blind treatment period, and then all enrolled patients continued to receive LY01011 until week 53.

View Article and Find Full Text PDF

Nocardiosis caused by is exceptionally rare and characterized by a high mortality rate. It typically affects immunocompromised patients, resulting in severe pulmonary or disseminated infections, and is notorious for abscess formation. Empyema resulting from nocardiosis is even less common.

View Article and Find Full Text PDF

Background: The 2021 Global Burden of Disease (GBD) study shows a continuous increase in the burden of chronic kidney disease due to diabetes mellitus type 2 (CKD-T2DM) from 1990 to 2021. This study examines the influence of dietary risk factors across various populations and socioeconomic groups.

Methods: Utilizing the 2021 GBD data, we analyzed age-standardized CKD-T2DM metrics-including mortality, disability-adjusted life years (DALY), and age-standardized rates (ASR)-stratified by age, gender, and region.

View Article and Find Full Text PDF

Metabolic syndrome-related diseases frequently involve disturbances in skeletal muscle lipid metabolism. The accumulation of lipid metabolites, lipid-induced mitochondrial stress in skeletal muscle cells, as well as the inflammation of adjacent adipose tissue, are associated with the development of insulin resistance and metabolic dysfunction. Consequently, when antidiabetic medications are used to treat various chronic conditions related to hyperglycaemia, the impact on skeletal muscle lipid metabolism should not be overlooked.

View Article and Find Full Text PDF

Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRAS-mutated nonsmall-cell lung cancer. The primary endpoint was the objective response rate (ORR) assessed by an independent review committee (IRC).

View Article and Find Full Text PDF
Article Synopsis
  • A phase 3 trial (CHOICE-01) showed that combining toripalimab with chemotherapy significantly improves progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC).
  • The final analysis revealed a median overall survival (OS) of 23.8 months for the toripalimab group compared to 17.0 months for the control group, particularly benefiting non-squamous patients.
  • The study also emphasized the role of circulating tumor DNA (ctDNA) and tissue-based sequencing in identifying biomarkers that predict treatment efficacy, suggesting continuous ctDNA monitoring could enhance personalized treatment strategies.
View Article and Find Full Text PDF
Article Synopsis
  • FGFR is a vital receptor involved in growth and tissue repair, but its gene mutations can lead to cancer by disrupting essential processes.
  • Small molecule drugs and antibodies targeting FGFR mutations, like erdafitinib and pemigatinib, have shown clinical efficacy in treating certain cancer types.
  • Effective screening methods for FGFR variants are essential for utilizing FGFR inhibitors in treatment, and a consensus has been developed to standardize diagnosis and treatment processes.
View Article and Find Full Text PDF

Importance: Patients with extensive-stage small cell lung cancer (ES-SCLC) have poor prognoses and unmet medical needs.

Objective: To evaluate the efficacy and safety of toripalimab plus etoposide and platinum-based chemotherapy (EP) vs placebo plus EP as a first-line treatment for patients with ES-SCLC.

Design, Setting, And Participants: This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (EXTENTORCH study) enrolled patients from September 26, 2019, to May 20, 2021, and was conducted at 49 sites in China.

View Article and Find Full Text PDF
Article Synopsis
  • * BRAF mutations are common in various cancers, and targeted therapies, especially BRAF inhibitors like dabrafenib and trametinib, are developed for treating solid tumors with these mutations.
  • * An expert consensus has been established to improve the diagnosis and treatment of solid tumors with BRAF mutations, focusing on summarizing their clinical features, recommending genetic testing methods, and creating a systematic approach for patient care.
View Article and Find Full Text PDF

Introduction: PEARL (NCT03003962) is an open-label, phase 3 study comparing first-line durvalumab monotherapy with chemotherapy in patients with metastatic NSCLC (mNSCLC [EGFR/ALK wild type]) with programmed cell death ligand 1 (PD-L1) tumor cell (TC) membrane expression status of 25% or higher. We report the final analysis of PEARL.

Methods: Adults (N = 669) with previously untreated stage IV mNSCLC were randomized (1:1) to durvalumab 20 mg/kg every four weeks or chemotherapy every three weeks for four to six cycles.

View Article and Find Full Text PDF

Background: Stereotactic body radiation therapy (SBRT) in treating non-small-cell lung cancer (NSCLC) exhibits a remarkable therapeutic efficacy. However, its effectiveness in overcoming resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR mutations (EGFRm) NSCLC remains uncertain.

Objective: We aimed to analyze the effect of SBRT on patients with first-line EGFR-TKIs.

View Article and Find Full Text PDF
Article Synopsis
  • * A phase II clinical trial tested a combination of anlotinib and S-1 in 52 eligible patients who had experienced disease progression after platinum-based chemotherapy.
  • * Results showed a 43.8% overall response rate and manageable side effects, indicating this treatment combination could be effective for relapsed or refractory SCLC patients.
View Article and Find Full Text PDF
Article Synopsis
  • Savolitinib has been approved in China for treating advanced non-small-cell lung cancer (NSCLC) with specific genetic mutations, particularly in patients who haven't had prior treatments or can't undergo platinum-based chemotherapy.
  • A phase 3b study evaluated the drug's safety and effectiveness in treatment-naive patients with these mutations across 48 hospitals in China, administering different dosages based on patient weight.
  • Results showed a promising objective response rate of 62% based on independent assessments, with the majority of patients experiencing some treatment-related side effects, the most common being peripheral edema.
View Article and Find Full Text PDF
Article Synopsis
  • Research seeks to improve chemotherapy and PD-1 inhibitors for advanced non-small-cell lung cancer (NSCLC) by analyzing circulating tumor DNA (ctDNA) from 460 patients in the CHOICE-01 study.
  • Key predictive markers such as ctDNA status, tumor mutational burden, and chromosomal instability were identified to tailor treatment strategies for better patient outcomes.
  • An integrated ctDNA-based stratification system, called blood-based genomic immune subtypes (bGIS), offers a new way to personalize therapies and monitor treatment responses in advanced NSCLC patients.
View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed the effectiveness of befotertinib, a drug for treating non-small cell lung cancer with EGFR T790M mutation, showing positive outcomes in patients with brain metastases and a manageable safety profile.
  • Two groups of patients received different doses of the drug, and after tracking their progress for nearly four years, the overall survival rates were reported as 23.9 months and 31.5 months for the lower and higher doses, respectively.
  • The results suggest that befotertinib offers significant overall survival benefits compared to other third-generation treatments, with adverse effects mostly manageable and in line with previous findings for similar cancer types.
View Article and Find Full Text PDF
Article Synopsis
  • A study called ANEAS compared two cancer treatments, aumolertinib and gefitinib, for patients with advanced lung cancer that had spread to the brain.
  • The results showed that aumolertinib worked much better, helping patients live longer without their brain cancer getting worse compared to gefitinib.
  • Overall, more patients treated with aumolertinib responded well to the treatment, showing an improvement in their condition compared to those who received gefitinib.
View Article and Find Full Text PDF
Article Synopsis
  • Patients with non-small cell lung cancer who experienced disease progression on EGFR tyrosine kinase inhibitors (TKIs), especially third-generation ones, have limited treatment options available.* -
  • The study aimed to compare the effectiveness of ivonescimab in conjunction with chemotherapy versus chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with EGFR variants.* -
  • Results showed that the median progression-free survival was significantly higher in the ivonescimab group (7.1 months) compared to the placebo group (4.8 months), indicating a promising benefit for those receiving ivonescimab.*
View Article and Find Full Text PDF

Background: Olgotrelvir is an oral antiviral with dual mechanisms of action targeting severe acute respiratory syndrome coronavirus 2 main protease (i.e., M) and human cathepsin L.

View Article and Find Full Text PDF
Article Synopsis
  • Fusion genes from the epidermal growth factor (EGF) receptor family are significant players in cancer development, especially in lung cancer, where gene fusion incidence is 0.19 to 0.27%.
  • Common partners for these fusions are CD74 and SLC3A2, and detection methods include RNA-based next-generation sequencing and pERBB3 immunohistochemistry for quick screening.
  • Currently, there are no approved specific drugs for these fusions, but treatment options like pan-ERBB inhibitors and monoclonal antibodies are being explored, with clinical trials aiming to improve outcomes for patients with solid tumors containing these gene fusions.
View Article and Find Full Text PDF

Background: microRNAs (miRNAs) are closely associated with the pathogenesis of various diseases, but the relationship between miRNAs and myocardial ischemia-reperfusion (I/R) injury remains unclear. Therefore, we aimed to explore the role and function of miRNAs and identify target genes regulating I/R.

Methods: We established a hypoxia/reoxygenation (H/R) model to detect differentially expressed miRNAs using high-throughput sequencing in rat myocardial cells.

View Article and Find Full Text PDF

Background: Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been proven a long-lasting treatment effect in pulmonary adenocarcinoma, most patients still progressed within one year due to the acquired resistance. Complex mutations of rare rare sites after acquiring resistance are rarely reported in pulmonary adenocarcinoma.

Case Presentation: A 62-year-old woman was diagnosed with pulmonary adenocarcinoma with stage IV.

View Article and Find Full Text PDF
Article Synopsis
  • The RET gene is a receptor tyrosine kinase involved in cell growth and differentiation; its fusion is a rare but poor-prognosis alteration in non-small cell lung cancer (NSCLC).
  • Two selective inhibitors, pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC, showing effectiveness against resistance to other treatments.
  • Effective patient screening for RET fusion is vital, utilizing methods like NGS, RT-PCR, FISH, and IHC, with the goal of standardizing approaches to improve diagnosis and therapy outcomes.
View Article and Find Full Text PDF

Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) show good selectivity for classical EGFR mutated and EGFR T790M mutated non-small cell lung cancer (NSCLC). However, resistance inevitably occurs to third-generation EGFR-TKI. This study describes the real-world characteristics, efficacy, and safety of treating post-progression NSCLC with 160 mg of furmonertinib (in combination with or without anti-angiogenic agents and chemotherapy) with third-generation EGFR-TKIs.

View Article and Find Full Text PDF